Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 No DAC: A Syntetic Peptide of GHRH - Biotech Peptides

CJC-1295 No DAC: A Synthetic Peptide of GHRH by Dr. Usman | Aug 8, 2022 | Research Contents: The Difference Between CJC-1295 and CJC-1295 DAC The Functions of CJC-1295 CJC-1295 and Hemorrhagic Shock and GHRH 1-29 Interaction CJC-1295 NO DAC and Growth CJC-1295

By Recovery & Performance Peptides Editorial Team

CJC-1295 No DAC: A Synthetic Peptide of GHRH

by Dr. Usman | Aug 8, 2022 | Research

Contents:

The Difference Between CJC-1295 and CJC-1295 DAC

The Functions of CJC-1295

CJC-1295 and Hemorrhagic Shock and GHRH 1-29 Interaction

CJC-1295 NO DAC and Growth

CJC-1295 NO DAC and Infertility

References

Featured Product

The Difference Between CJC-1295 and CJC-1295 DAC

These two peptides seem similar but are not identical. CJC-1295 is a modified equivalent of the first 29 amino acids of GHRH, chemically identical to other growth hormone analogs like Sermorelin. Meanwhile, CJC-1295 DAC is created by adding the Drug Affinity Complex DAC, to CJC-1295. DAC is added to CJC-1295 using the lysine linker. The DAC appears to protect CJC-1295 while it circulates in the bloodstream. DAC may ensure the increased half-life of CJC-1295 by allowing the peptide to bind to blood proteins such as Albumin.

The Functions of CJC-1295

CJC-1295 NO DAC appears to function to enhance protein synthesis. The peptide may achieve this by inhibiting the natural process of cellular degradation, thereby increasing protein synthesis. The peptide may also potentially improve lipolytic processes by increasing the rate of synthesis and disintegration. By increasing the lipolytic process, CJC-1295 NO DAC peptide may influence the increased efficiency of fat cell dissolution.

CJC-1295 and Hemorrhagic Shock and GHRH 1-29 Interaction

CJC-1295 NO DAC has been hypothesized to stimulate and improve nerve reflexes within the brain and may modulate blood flow, thereby preventing acute organ failure following hemorrhagic shock. On the other hand, hemorrhagic shock may be an acute condition followed by reduced tissue perfusion and insufficient nutrient and oxygen delivery necessary for cellular functions. Hemorrhagic shock is classified as cardiogenic, hypovolemic, septic, and neurogenic.

CJC-1295 NO DAC and Growth

The peptide is considered a potential enhancing agent for maintaining the normal rate of growth hormone release.[1] By doing this, the peptide may exert action in cases of abnormal growth in varieties of animal species. Maintaining the normal growth hormone level may be critical to releasing downstream hormones like insulin-like growth factor-2 (IGF-1). CJC-1295 appears to significantly enhance the synthesis of IGF-1. GH, CJC-1295, and IGF-1 collectively influence the pro-inflammatory mechanisms when activated.

In mouse models of GHRH knockout, the exposure to CJC-1295 appeared to reduce growth deficits. Furthermore, CJC-1295 appeared to steadily enhance the total body weight and length.[2] This study reports that “These findings [indicate that exposure to] CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice.” The peptide also assessed the abnormal response to GRF following obesity.

CJC-1295 and Infertility

Scientists suggest GRF analogs, CJC-1295, might induce ovulation in infertile female species. Data findings imply that ovulation may be solely dependent on IGF-1 and may be regulated by the release and cycling of growth hormones. However, research in mouse models of superovulation suggest that the levels of IGF-1 and growth hormone may increase with ovulation.[3] These results posit that the exposure to a GH secretagogue like CJC-1295 may induce ovulation. Scientific research also suggests that CJC-1295 NO DAC and other GHRH analogs may impact male infertility by inducing sperm production. However, note that this hypothesis is still undergoing testing.[4] The researchers report that “these results led to the identification of CJC-1295 as a stable and active hGRF1-29 analogwith an extended plasma half-life.”

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.

Volpe A, Coukos G, Barreca A, Giordano G, Artini PG, Genazzani AR. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum Reprod. 1991 Oct;6(9):1228-32. doi: 10.1093/oxfordjournals.humrep.a137517. PMID: 1752922.

Jetté, Lucie, et al. “hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.” (2005)

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.

Dr. Usman

Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.

Latest Post

BPC157: Molecular Characterization, Pleiotropic Signaling Mechanisms, and Preclinical Research

Copper Peptides: Molecular Characterization, Mechanistic Biology, and Emerging Research

Modified GRF 1-29 and GHRP-2 Peptide Blend: Receptor Pharmacology, Somatotroph Signaling, and Neuroendocrine Research

Fragment 176-191, Modified GRF 1-29, and Ipamorelin Blend: Adipose Metabolism, GH Axis Modulation, and Receptor Signaling Research

PNC-27: Structural Characterization, HDM-2-Dependent Membrane Targeting, and Selective Tumor Cell Necrosis

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Incorporate CJC-1295 No DAC in Your Research

Proper handling is essential to maintain the integrity of your research compounds. Our CJC-1295 No DAC arrives as a lyophilized (freeze-dried) powder to ensure maximum stability during shipping to your San Antonio lab. Before use, it must be reconstituted with a sterile solvent, with Bacteriostatic Water being the standard for most research protocols. Once reconstituted, the solution should be stored under refrigeration to preserve its potency. Following precise, documented protocols is key to achieving consistent and reproducible data in your studies. At Real Peptides, we empower you by providing the highest purity starting materials, so you can focus on the integrity of your experimental design. When your research demands accuracy, starting with premium, verifiable peptides isn't just an option—it's a requirement for success. Find the Right Peptide Tools for Your Lab
STORAGE

Reconstitution, Storage, and the Vial Size Dilemma

This is where the rubber meets the road. The process of reconstitution is inextricably linked to your chosen CJC-1295 no DAC vial size. Reconstituting a 2mg vial of CJC 1295 (no Dac) with 1mL of bacteriostatic water gives you a concentration of 200mcg per 0.1mL. Simple. Reconstituting a 5mg vial with 2mL of water gives you 250mcg per 0.1mL. The math can get more complex, and with complexity comes a higher chance of error. Your choice of CJC-1295 no DAC vial size directly influences how easy or difficult this critical step will be. We can't talk about this without discussing storage. Once reconstituted, CJC-1295 (no DAC) must be kept refrigerated. The stability of the peptide in solution is finite—typically, our team recommends using it within 30 days for optimal potency, though sooner is always better. A larger vial is, by definition, going to be stored for a longer period. This extended storage time, combined with repeated punctures of the septum, creates a formidable challenge to maintaining sterility and potency. Each access event is a potential contamination vector. A smaller CJC-1295 no DAC vial size drastically reduces the number of these events and the total time the reconstituted solution is stored. This is a critical risk-management strategy for any serious laboratory. The physical integrity of the vial matters, too. At Real Peptides, we ensure every vial, regardless of the CJC-1295 no DAC vial size, is sealed under sterile conditions with a high-quality rubber sept…
02

Question drills

Open a question for its connected answer.

01What If the Syringe Has Air Bubbles That Won't Rise to the Top?+

Flick the syringe barrel sharply with your fingernail 5–10 times while holding it needle-up. The mechanical vibration dislodges small bubbles adhered to the barrel wall, allowing them to coalesce and rise. If bubbles remain: (1) Tap more firmly, (2) Draw an additional 0.1mL of air into the syringe and then expel everything slowly. The increased air volume often pushes stubborn bubbles out, (3) If still unsuccessful, expel the dose back into the vial and redraw with a fresh syringe. Persistent micro-bubbles in bacteriostatic water sometimes indicate the water itself is contaminated or has been stored open to atmosphere, allowing dissolved gases to come out of solution. Check the bacteriostatic water vial for contamination and replace if older than 28 days after first puncture.

SOURCE / realpeptides.co ↗
02What If Human Trial Results Show Lower Efficacy Than Animal Studies Suggested?+

You're observing the expected outcome. Somatostatin feedback, hepatic first-pass metabolism, and receptor saturation ceiling all suppress human GH response relative to rodent models. A 'disappointing' human trial that shows 2.5-fold GH elevation isn't a failure. It's consistent with species-specific physiology that animal models can't replicate.

SOURCE / realpeptides.co ↗
03What If My Protocol Requires Daily Dosing for 8+ Weeks?+

Select Ipamorelin (200–300 mcg once or twice daily) or GHRP-2 (100–200 mcg twice daily). Both maintain GH pulse response across extended timelines without the desensitization observed with Hexarelin. Ipamorelin is preferred if cortisol or prolactin elevation would confound your experimental endpoints; GHRP-2 is preferred if hunger signaling or ghrelin pathway activation is part of the metabolic context you're studying.

SOURCE / realpeptides.co ↗
04What If I See Cloudiness After Reconstitution?+

Cloudiness indicates peptide aggregation. Multiple peptide molecules clumping together into insoluble complexes. This occurs from aggressive reconstitution (shaking, direct injection onto powder), contamination, or use of non-sterile water. Aggregated peptides lose biological activity because the receptor-binding region is buried inside the aggregate. Do not use cloudy solutions. Allow the vial to sit undisturbed for 10 minutes; if cloudiness persists, discard the vial. Aggregation is irreversible. Refrigeration or additional dilution will not restore clarity or potency.

SOURCE / realpeptides.co ↗
05What If My Reconstituted CJC-1295 No DAC Has Been Refrigerated for 6 Weeks?+

Expect reduced bioavailability even if the solution appears clear and colorless. Peptide bonds undergo gradual hydrolysis during refrigerated storage, fragmenting intact CJC-1295 No DAC into inactive peptide sequences. Research shows bioactivity declines 8–12% between weeks 4–6 and 15–25% after 8 weeks, even at proper refrigeration temperatures (2–8°C). Visual inspection can't detect this fragmentation. Only plasma GH response reveals the loss. Reconstitute smaller volumes more frequently rather than storing large batches long-term.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

How Real Peptides Supports Your CJC-1295 no DAC Research

At Real Peptides, our mission extends beyond simply supplying high-purity peptides. We see ourselves as a partner in your scientific endeavors. We stand behind every product we sell, from our CJC 1295 (no Dac) to our comprehensive All Peptides collection, ensuring you have a trusted partner in your research. Our commitment to quality, backed by rigorous testing and transparent Certificates of Analysis, is unwavering. We understand the demanding schedules and high expectations that come with cutting-edge biological research, and we strive to make your procurement process as seamless and reliable as possible. We’re constantly engaging with the scientific community, gathering insights, and refining our offerings based on the latest research trends and feedback. Our support team is comprised of individuals with a deep understanding of the biotechnology industry, ready to assist with your questions regarding product specifications, handling, and potential research applications. We believe that by providing exceptional quality and knowledgeable support, we empower researchers to push the boundaries of discovery. Find the right peptide tools for your lab and let us help you achieve your research objectives. This unwavering support is a cornerstone of our approach to every CJC-1295 no DAC FAQ and beyond.

RESEARCH

Why Researchers Choose CJC-1295 No DAC

In the world of peptide research, control and precision are everything. For scientists and lab professionals in Minneapolis, the choice between different peptide analogs can define the outcome of a study. This is precisely why so many are turning to CJC-1295 No DAC, also known as Modified GRF 1-29. Unlike its long-acting counterpart, this peptide is designed for a completely different research model, one that values subtlety and biomimicry over sustained action. The fundamental appeal of CJC 1295 NO DAC lies in its short half-life, which is typically around 30 minutes. This characteristic allows it to stimulate a release of growth hormone from the pituitary in a pulsatile manner, closely mimicking the body's natural rhythms. For studies aiming to understand the nuanced effects of GH spikes—on cellular repair, metabolism, or muscle tissue development—this peptide provides an invaluable tool. The alternative, CJC-1295 with DAC, creates a prolonged elevation of GH levels, which, while useful for certain studies, doesn't replicate this natural physiological pulse. This makes CJC-1295 No DAC a superior choice for protocols where researchers need to observe the effects of distinct, separate GH pulses rather than a constant, elevated presence. It provides the ability to administer the compound and study its short-term downstream effects with minimal overlap, ensuring cleaner data and more accurate conclusions. This level of control is essential for rigorous scientific inquiry, a standard we uphold across our entire peptide collection.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles